Tissue Microarray Availability Section	***Description***
2.1	Tissue Sites Summary
2.2	Tissue Microarray and DNA Core Availability by Tissue Site
2.3	Biospecimen Availability by Tissue Site
2.4	PLCO Study Demographics by Tissue Site
2.5	Tissue Site Cancer and Adenoma Characteristics

Table 2.1: Tissue Sites Summary

Tissue Site	*TMA Slides Status*	*DNA Cores Status*	*Other Tissue Information*
Prostate	TMA blocks are available for selection.	DNA cores are currently available for selection.	Prostate tissue was selected in Fall 2007. Subjects with a prostatectomy, and who were in CGEMS or had blood/buccal cell available were selected. One-half of the eligible cases with buccal cell, not in CGEMS, were selected. The CGEMS cases' prostate cores were preferentially selected; TMA blocks have been organized into CGEMS vs. non-CGEMS boxes. A separate tissue selection for subjects from the PCP study was later conducted.
Lung	TMA blocks are available for selection.	DNA cores are currently available for selection.	Lung tissue was selected in Fall 2009. Subjects targeted for tissue were: never smokers, interval cancers, small aggressive lung cancers, and African Americans. Subjects were identified for selection if they had evidence of a biopsy, or surgery obtaining tissue.
Colorectal	TMA blocks are available for selection.	DNA has been extracted from cores. RNA lysates remain unprocessed as RNA source.	Colon tissue was selected in Spring 2006. All eligible subjects were targeted for selection, including a small number of multiple-primary cases. The cases are split into pre-treatment and post-treatment tissue. An additional selection was done in Fall 2013.
Ovarian	TMA blocks are available for selection.	DNA cores are currently available for selection.	Ovary tissue was selected in two waves. The first set of ovary tissue was selected in Summer 2006, and the second in Fall 2010. Subjects with either Path T or an Oophorectomy were identified for selection. Cancer cases included invasive ovarian, fallopian tube, and primary peritoneals.
Adenoma	TMA blocks are available for selection.	DNA has been extracted from cores. RNA lysates remain unprocessed as RNA source.	Adenoma Tissue was selected in Spring 2007. Selection groups included: ACF subjects, African Americans, and participants with Recurrent Adenomas, Incident Adenomas, and Prevalent Adenomas; preference was taken in selecting non-Prevalent adenomas. Only 300 subjects were taken from each study center for adenoma tissue. Only large adenomas were selected because of concerns that there would not be enough material to array.
Breast	TMA blocks are available for selection.	DNA cores are currently available for selection.	Breast tissue was selected in Fall 2010. Tissue was preferentially selected if the participant was included in the Breast CGEMS study. Invasive cancers were also preferentially selected over In-Situ cases. Only tumors size 0.5cm or greater were selected. An additional selection consisting of in situs exclusively was done in Fall 2012 using the same criteria as the Fall 2010 selection.
Male Breast	TMA blocks are available for selection.	DNA cores are currently available for selection.	Male Breast tissue was selected in Fall 2010. All 27 cases were selected for tissue extraction, including cases where the cancer was reported but not yet confirmed. Unlike female breast cancer, tumor size was not taken into account in selection.
Bladder	TMA blocks are available for selection.	DNA cores are currently available for selection.	Bladder tissue was selected in Fall 2012. All available invasive and in situ cases of specific morphologies were selected.

Table 2.2.1: Tissue Microarray and DNA Core Availability by Tissue Site

	Tissue Site							
	Prostate	***Lung***	***Colorectal***	***Ovarian***	***Adenoma***	***Breast***	***Male Breast***	***Bladder***
Selected by IMS	1652	1030	1398	321	2468	1852	27	880
With Donor Blocks Received	1100	502	777	228	871	1025	18	293
With TMA Cores	1091	434	673	212	658	801	17	201
With TMA Tumor Cores	917	434	630	195	658	801	17	201
With DNA Cores	697	433	143	211	6	768	17	124
With TMA Cores and DNA Cores	697	433	142	211	6	768	17	124
With TMA Cores or DNA Cores	1091	434	674	212	658	801	17	201

Table 2.2.2: Tissue Microarray and DNA Core Availability by Tissue Site and Phase for Sites with Multiple Selections

	Tissue Site										
	Prostate			*Colorectal*			*Ovarian*		*Breast*		
	Non CGEMS	*CGEMS*	*PCP*	*Pre TX*	*Post TX*	*Second Selection*	*Selection 1*	*Selection 2*	*Selection 1*	*Selection 2*	*In Situ selection*
Selected by IMS	898	649	105	847	33	518	183	138	881	653	318
With Donor Blocks Received	633	428	39	533	20	224	136	92	547	383	95
With TMA Cores	631	421	39	486	12	175	130	82	473	328	0
With TMA Tumor Cores	538	379	0	454	12	164	119	76	473	328	0
With DNA Cores	365	332	0	1	0	142	129	82	452	316	0
With TMA Cores and DNA Cores	365	332	0	0	0	142	129	82	452	316	0
With TMA Cores or DNA Cores	631	421	39	487	12	175	130	82	473	328	0

Table 2.3: Biospecimen Availability by Tissue Site

	Tissue Site and Core Type															
	Prostate		***Lung***		***Colorectal***		***Ovarian***		***Adenoma***		***Breast***		***Male Breast***		***Bladder***	
	TMA	***DNA***	***TMA***	***DNA***	***TMA***	***DNA***	***TMA***	***DNA***	***TMA***	***DNA***	***TMA***	***DNA***	***TMA***	***DNA***	***TMA***	***DNA***
All	1091	697	434	433	673	143	212	211	658	6	801	768	17	17	201	124
RBC (Pre-DX)	826	544	243	242	290	67	105	104	563	5	577	550	9	9	93	61
Serum (Pre-DX)	810	529	238	237	279	64	102	101	557	4	569	542	9	9	96	63
Plasma (Pre-DX)	795	521	166	165	274	63	103	102	548	5	560	533	9	9	95	62
EDTA Plasma (Pre-DX)	342	194	131	130	136	48	64	63	124	2	327	308	8	8	77	49
Heparin Plasma (Pre-DX)	792	518	162	161	271	63	102	101	548	5	556	529	9	9	94	61
Serum + DNA (Pre-DX)	755	495	231	230	248	61	99	98	525	3	554	527	9	9	93	60
Serum (Post-DX)	478	329	88	88	120	3	31	30	419	3	256	246	2	2	16	12
Plasma (Post-DX)	493	341	94	94	119	5	33	32	402	3	266	254	2	2	17	11
EDTA Plasma (Post-DX)	493	341	94	94	119	5	33	32	401	3	266	254	2	2	16	10
Heparin Plasma (Post-DX)	327	240	62	62	86	4	20	20	353	3	130	124	1	1	9	6
Serum + DNA (Post-DX)	463	318	86	86	114	3	30	29	398	3	255	245	2	2	16	12
Serum (Pre-DX & Post-DX)	467	322	88	88	109	3	28	27	410	1	251	241	2	2	16	12
Any DNA	1017	656	358	357	399	128	166	165	536	5	729	697	9	9	162	94
GWAS Avail.	973	630	324	323	483	113	165	164	181	1	186	183	4	4	103	68

Table is based on selected subjects with either TMA or DNA cores available.

Table 2.4: PLCO Study Demographics by Tissue Site

	Tissue Site															
	Prostate		*Lung*		*Colorectal*		*Ovarian*		*Adenoma*		*Breast*		*Male Breast*		*Bladder*	
	Selected	*TMA or DNA*	*Selected*	*TMA or DNA*	*Selected*	*TMA or DNA*	*Selected*	*TMA or DNA*	*Selected*	*TMA or DNA*	*Selected*	*TMA or DNA*	*Selected*	*TMA or DNA*	*Selected*	*TMA or DNA*
All	1652	1091	1030	434	1398	674	321	212	2468	658	1852	801	27	17	880	201
Randomization Group																
Control	394	239	402	173	691	341	122	88	96	36	590	201	10	6	427	93
Intervention	1258	852	628	261	707	333	199	124	2372	622	1262	600	17	11	453	108
Gender																
Female	0	0	453	185	599	285	321	212	811	210	1852	801	.	.	157	47
Male	1652	1091	577	249	799	389	0	0	1657	448	0	0	27	17	723	154
Race																
White, Non-Hispanic	1488	993	882	389	1238	598	295	192	2203	556	1647	714	23	14	839	189
Black, Non-Hispanic	103	56	94	22	72	34	9	5	214	80	107	57	2	1	14	2
Hispanic	26	19	12	1	19	10	4	4	24	8	22	6	0	0	10	1
Asian	26	15	23	10	54	23	7	7	21	11	50	14	0	0	13	8
Pacific Islander	6	6	1	0	4	2	0	0	0	0	10	3	0	0	3	1
American Indian	3	2	0	0	3	2	0	0	3	2	3	0	0	0	1	0
Missing	0	0	18	12	8	5	6	4	3	1	13	7	2	2	0	0
Study Center																
University of Colorado	166	117	53	18	111	72	25	20	213	77	179	75	4	3	86	21
Georgetown University	62	35	61	19	58	14	23	15	158	66	119	35	2	1	69	11
Pacific Health Research and Education Institute (Honolulu)	27	17	43	16	80	39	9	8	11	4	66	18	5	4	36	17
Henry Ford Health System	197	122	143	50	209	89	42	31	317	87	269	115	1	1	130	26
University of Minnesota	444	332	206	122	246	114	60	41	456	93	294	175	4	2	199	38
Washington University in St Louis	118	95	119	47	152	69	30	23	225	114	213	85	2	0	85	22
University of Pittsburgh	193	121	129	32	178	78	45	19	390	83	209	52	3	2	109	14
University of Utah	173	101	70	19	130	55	41	24	225	73	191	68	3	1	58	11
Marshfield Clinic Research Foundation	225	133	139	90	189	135	33	26	334	37	205	118	2	2	108	41
University of Alabama at Birmingham	47	18	67	21	45	9	13	5	139	24	107	60	1	1	0	0
Fiscal Year Of Randomization																
1994	143	76	57	23	114	54	15	11	177	37	113	40	2	2	81	15
1995	380	233	224	101	300	151	58	42	431	117	245	106	3	1	228	44
1996	349	216	182	77	251	132	60	40	553	156	340	161	8	4	162	49
1997	297	221	144	57	221	94	57	38	454	134	317	140	4	2	145	33
1998	178	124	145	62	168	91	54	36	296	73	287	120	2	0	101	20

Table 2.4: PLCO Study Demographics by Tissue Site

	Tissue Site															
	Prostate		*Lung*		*Colorectal*		*Ovarian*		*Adenoma*		*Breast*		*Male Breast*		*Bladder*	
	Selected	*TMA or DNA*	*Selected*	*TMA or DNA*	*Selected*	*TMA or DNA*	*Selected*	*TMA or DNA*	*Selected*	*TMA or DNA*	*Selected*	*TMA or DNA*	*Selected*	*TMA or DNA*	*Selected*	*TMA or DNA*
1999	165	118	151	62	198	91	48	26	329	82	294	113	8	8	104	28
2000	116	90	97	45	112	51	23	15	175	47	215	99	0	0	48	11
2001	24	13	30	7	34	10	6	4	53	12	41	22	0	0	11	1
Cigarette Smoking Status																
Ambiguous	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
No Form	0	0	18	12	8	5	6	4	1	0	13	7	2	2	0	0
Not Answered	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Never Smoked Cigarettes	690	433	137	34	600	298	170	107	936	226	980	440	12	7	215	43
Current Cigarette Smoker	137	99	393	176	165	75	30	21	357	112	178	73	3	1	149	42
Former Cigarette Smoker	825	559	482	212	625	296	115	80	1174	320	681	281	10	7	516	116

Table 2.5.1: Prostate Tissue Availability by Prostate Cancer Characteristics

	Prostate											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
All	1652	100.0	1091	100.0	917	100.0	697	100.0	697	100.0	1091	100.0
Prostate Cancer Status												
Confirmed Cancer	1652	100.0	1091	100.0	917	100.0	697	100.0	697	100.0	1091	100.0
Cancer Has Advanced Stage/Gleason												
Not Advanced	733	44.4	483	44.3	369	40.2	244	35.0	244	35.0	483	44.3
Somewhat Advanced (Gleason 7)	411	24.9	284	26.0	256	27.9	203	29.1	203	29.1	284	26.0
Advanced (Gleason 8,9,10, or Stage III,IV)	508	30.8	324	29.7	292	31.8	250	35.9	250	35.9	324	29.7
Gleason Score - Prostatectomy												
Missing	7	0.4	7	0.6	7	0.8	5	0.7	5	0.7	7	0.6
2	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
3	6	0.4	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
4	32	1.9	17	1.6	8	0.9	5	0.7	5	0.7	17	1.6
5	180	10.9	98	9.0	82	8.9	59	8.5	59	8.5	98	9.0
6	612	37.0	428	39.2	338	36.9	234	33.6	234	33.6	428	39.2
7	595	36.0	403	36.9	359	39.1	289	41.5	289	41.5	403	36.9
8	105	6.4	76	7.0	69	7.5	62	8.9	62	8.9	76	7.0
9	85	5.1	50	4.6	45	4.9	36	5.2	36	5.2	50	4.6
10	4	0.2	4	0.4	4	0.4	3	0.4	3	0.4	4	0.4
No Answer Given	24	1.5	7	0.6	4	0.4	3	0.4	3	0.4	7	0.6
Prostate Cancer Stage												
No Evidence of Tumor	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Stage II	1220	73.8	823	75.4	676	73.7	486	69.7	486	69.7	823	75.4
Stage III	378	22.9	231	21.2	209	22.8	183	26.3	183	26.3	231	21.2
Stage IV	53	3.2	37	3.4	32	3.5	28	4.0	28	4.0	37	3.4
Prostate Cancer Histopathologic Type												
Adenocarcinoma, NOS	1462	88.5	972	89.1	817	89.1	624	89.5	624	89.5	972	89.1
Adenocarcinoma, Acinar	183	11.1	115	10.5	96	10.5	69	9.9	69	9.9	115	10.5
Adenocarcinoma, Mucinous	5	0.3	3	0.3	3	0.3	3	0.4	3	0.4	3	0.3
Adenocarcinoma, Ductal	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

Table 2.5.1: Prostate Tissue Availability by Prostate Cancer Characteristics

	Prostate											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
Carcinoma, NOS	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
Prostate Pathologic T (Primary Tumor)												
TX	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
T0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
T1C	3	0.2	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
T2	46	2.8	22	2.0	13	1.4	9	1.3	9	1.3	22	2.0
T2A	291	17.6	183	16.8	132	14.4	83	11.9	83	11.9	183	16.8
T2B	676	40.9	501	45.9	429	46.8	316	45.3	316	45.3	501	45.9
T2C	182	11.0	99	9.1	89	9.7	70	10.0	70	10.0	99	9.1
T3	25	1.5	15	1.4	13	1.4	12	1.7	12	1.7	15	1.4
T3A	234	14.2	147	13.5	137	14.9	124	17.8	124	17.8	147	13.5
T3B	108	6.5	73	6.7	63	6.9	51	7.3	51	7.3	73	6.7
T3C	33	2.0	14	1.3	11	1.2	9	1.3	9	1.3	14	1.3
T4	17	1.0	11	1.0	9	1.0	8	1.1	8	1.1	11	1.0
T4A	5	0.3	2	0.2	2	0.2	2	0.3	2	0.3	2	0.2
Not Available	30	1.8	22	2.0	17	1.9	11	1.6	11	1.6	22	2.0
Prostate Pathologic N (Nodal Involvement)												
NX	174	10.5	98	9.0	84	9.2	57	8.2	57	8.2	98	9.0
N0	1413	85.5	943	86.4	793	86.5	608	87.2	608	87.2	943	86.4
N1	28	1.7	22	2.0	19	2.1	17	2.4	17	2.4	22	2.0
N2	3	0.2	2	0.2	2	0.2	1	0.1	1	0.1	2	0.2
Not Available	34	2.1	26	2.4	19	2.1	14	2.0	14	2.0	26	2.4
Prostate Pathologic M (Distant Metastases)												
MX	216	13.1	126	11.5	100	10.9	69	9.9	69	9.9	126	11.5
M0	1404	85.0	942	86.3	799	87.1	616	88.4	616	88.4	942	86.3
M1B	2	0.1	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
Not Available	30	1.8	22	2.0	17	1.9	11	1.6	11	1.6	22	2.0

Table 2.5.2: Lung Tissue Availability by Lung Cancer Characteristics

	Lung											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
All	1030	100.0	434	100.0	434	100.0	433	100.0	433	100.0	434	100.0
Lung Cancer Status												
Confirmed Cancer	1030	100.0	434	100.0	434	100.0	433	100.0	433	100.0	434	100.0
Lung Cancer Stage												
Stage I	5	0.5	1	0.2	1	0.2	1	0.2	1	0.2	1	0.2
Stage IA	287	27.9	157	36.2	157	36.2	157	36.3	157	36.3	157	36.2
Stage IB	211	20.5	122	28.1	122	28.1	122	28.2	122	28.2	122	28.1
Stage II	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Stage IIA	25	2.4	16	3.7	16	3.7	16	3.7	16	3.7	16	3.7
Stage IIB	74	7.2	38	8.8	38	8.8	38	8.8	38	8.8	38	8.8
Stage IIIA	86	8.3	39	9.0	39	9.0	38	8.8	38	8.8	39	9.0
Stage IIIB	79	7.7	23	5.3	23	5.3	23	5.3	23	5.3	23	5.3
Stage IV	190	18.4	30	6.9	30	6.9	30	6.9	30	6.9	30	6.9
Small cell	72	7.0	8	1.8	8	1.8	8	1.8	8	1.8	8	1.8
Lung Cancer Grade												
Grade Cannot Be Assessed (GX)	61	5.9	7	1.6	7	1.6	7	1.6	7	1.6	7	1.6
Well Differentiated (G1)	105	10.2	52	12.0	52	12.0	52	12.0	52	12.0	52	12.0
Moderately Differentiated (G2)	309	30.0	170	39.2	170	39.2	170	39.3	170	39.3	170	39.2
Poorly Differentiated (G3)	350	34.0	160	36.9	160	36.9	160	37.0	160	37.0	160	36.9
Undifferentiated (G4)	56	5.4	16	3.7	16	3.7	16	3.7	16	3.7	16	3.7
Unknown	149	14.5	29	6.7	29	6.7	28	6.5	28	6.5	29	6.7
Lung Cancer Histopathologic Type												
Squamous Cell Carcinoma	228	22.1	115	26.5	115	26.5	115	26.6	115	26.6	115	26.5
Spindle Cell Carcinoma	5	0.5	3	0.7	3	0.7	3	0.7	3	0.7	3	0.7
Small Cell Carcinoma	68	6.6	7	1.6	7	1.6	7	1.6	7	1.6	7	1.6
Intermediate Cell Carcinoma	2	0.2	1	0.2	1	0.2	1	0.2	1	0.2	1	0.2
Adenocarcinoma	384	37.3	172	39.6	172	39.6	171	39.5	171	39.5	172	39.6
Acinar Adenocarcinoma	11	1.1	6	1.4	6	1.4	6	1.4	6	1.4	6	1.4
Papillary Adenocarcinoma	11	1.1	8	1.8	8	1.8	8	1.8	8	1.8	8	1.8

Table 2.5.2: Lung Tissue Availability by Lung Cancer Characteristics

	Lung											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
Bronchioalveolar Adenocarcinoma	117	11.4	50	11.5	50	11.5	50	11.5	50	11.5	50	11.5
Adenocarcinoma w/Mucus Formation	16	1.6	4	0.9	4	0.9	4	0.9	4	0.9	4	0.9
Large Cell Carcinoma	45	4.4	20	4.6	20	4.6	20	4.6	20	4.6	20	4.6
Clear Cell Carcinoma	4	0.4	2	0.5	2	0.5	2	0.5	2	0.5	2	0.5
Adenosquamous Carcinoma	39	3.8	25	5.8	25	5.8	25	5.8	25	5.8	25	5.8
Adenoid Cystic Carcinoma	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Non-small cell (recoded)	58	5.6	12	2.8	12	2.8	12	2.8	12	2.8	12	2.8
Carcinoma NOS (recoded)	14	1.4	1	0.2	1	0.2	1	0.2	1	0.2	1	0.2
Mixed small and non-small cell (recoded)	2	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Neuroendocrine NOS (recoded)	25	2.4	8	1.8	8	1.8	8	1.8	8	1.8	8	1.8
Lung Cancer Type (Categorized)												
Confirmed lung cancer	1030	100.0	434	100.0	434	100.0	433	100.0	433	100.0	434	100.0
Lung Cancer Pathologic T (Primary Tumor)												
TX	17	1.7	3	0.7	3	0.7	3	0.7	3	0.7	3	0.7
T1	337	32.7	184	42.4	184	42.4	184	42.5	184	42.5	184	42.4
T2	310	30.1	182	41.9	182	41.9	182	42.0	182	42.0	182	41.9
T3	42	4.1	16	3.7	16	3.7	16	3.7	16	3.7	16	3.7
T4	56	5.4	26	6.0	26	6.0	26	6.0	26	6.0	26	6.0
TNM not available	268	26.0	23	5.3	23	5.3	22	5.1	22	5.1	23	5.3
Lung Cancer Pathologic N (Nodal Involvement)												
NX	40	3.9	17	3.9	17	3.9	17	3.9	17	3.9	17	3.9
N0	544	52.8	297	68.4	297	68.4	297	68.6	297	68.6	297	68.4
N1	102	9.9	56	12.9	56	12.9	55	12.7	55	12.7	56	12.9
N2	72	7.0	40	9.2	40	9.2	40	9.2	40	9.2	40	9.2
N3	7	0.7	3	0.7	3	0.7	3	0.7	3	0.7	3	0.7
TNM not available	265	25.7	21	4.8	21	4.8	21	4.8	21	4.8	21	4.8
Lung Cancer Pathologic M (Distant Metastases)												
MX	71	6.9	26	6.0	26	6.0	26	6.0	26	6.0	26	6.0
M0	632	61.4	362	83.4	362	83.4	361	83.4	361	83.4	362	83.4

Table 2.5.2: Lung Tissue Availability by Lung Cancer Characteristics

	Lung											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
M1	63	6.1	25	5.8	25	5.8	25	5.8	25	5.8	25	5.8
TNM not available	264	25.6	21	4.8	21	4.8	21	4.8	21	4.8	21	4.8

Table 2.5.3: Colorectal Tissue Availability by Colorectal Cancer Characteristics

	Colorectal											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
All	1398	100.0	673	100.0	630	100.0	143	100.0	142	100.0	674	100.0
Colorectal Cancer Status												
No Cancer	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Confirmed Cancer	1378	98.6	671	99.7	628	99.7	143	100.0	142	100.0	672	99.7
Erroneous Report of Cancer	4	0.3	1	0.1	1	0.2	0	0.0	0	0.0	1	0.1
Confirmed In Situ	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Borderline Malignancy	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Confirmed Non-target Cancer	13	0.9	1	0.1	1	0.2	0	0.0	0	0.0	1	0.1
Colorectal Cancer Stage												
No Form	5	0.4	1	0.1	1	0.2	0	0.0	0	0.0	1	0.1
Stage 0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Stage I	506	36.2	219	32.5	207	32.9	40	28.0	40	28.2	219	32.5
Stage II	353	25.3	184	27.3	174	27.6	45	31.5	45	31.7	184	27.3
Stage III	329	23.5	204	30.3	186	29.5	47	32.9	46	32.4	205	30.4
Stage IV	164	11.7	65	9.7	62	9.8	11	7.7	11	7.7	65	9.6
Carcinoid, Cannot be Assessed	37	2.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cannot be Assessed	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
TNM Not Available	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Colorectal Cancer Grade												
No Form	5	0.4	1	0.1	1	0.2	0	0.0	0	0.0	1	0.1
Grade Cannot Be Assessed (GX)	20	1.4	2	0.3	1	0.2	0	0.0	0	0.0	2	0.3
Well Differentiated (G1)	151	10.8	65	9.7	63	10.0	17	11.9	17	12.0	65	9.6
Moderately Differentiated (G2)	897	64.2	470	69.8	446	70.8	86	60.1	85	59.9	471	69.9
Poorly Differentiated (G3)	238	17.0	122	18.1	112	17.8	37	25.9	37	26.1	122	18.1
Undifferentiated (G4)	16	1.1	4	0.6	4	0.6	2	1.4	2	1.4	4	0.6
Unknown	71	5.1	9	1.3	3	0.5	1	0.7	1	0.7	9	1.3
Colorectal Cancer Type												
No Form	5	0.4	1	0.1	1	0.2	0	0.0	0	0.0	1	0.1
Carcinoma Insitu	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

Table 2.5.3: Colorectal Tissue Availability by Colorectal Cancer Characteristics

	Colorectal											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
Adenocarcinoma NOS	1187	84.9	596	88.6	579	91.9	126	88.1	125	88.0	597	88.6
Mucinous Adenocarcinoma	138	9.9	69	10.3	45	7.1	14	9.8	14	9.9	69	10.2
Signet Ring Cell Carcinoma	14	1.0	5	0.7	3	0.5	2	1.4	2	1.4	5	0.7
Squamous Cell Carcinoma	3	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Undifferentiated Carcinoma	2	0.1	1	0.1	1	0.2	1	0.7	1	0.7	1	0.1
Carcinoma NOS	7	0.5	1	0.1	1	0.2	0	0.0	0	0.0	1	0.1
Carcinoma, NOS	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Adenocarcinoid	3	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Carcinoid/neuroendocrine carcinoma	34	2.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Primary Lymphoma - all types	3	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Colorectal Cancer Pathologic T - Tumor												
No Form	5	0.4	1	0.1	1	0.2	0	0.0	0	0.0	1	0.1
TX	6	0.4	1	0.1	1	0.2	1	0.7	1	0.7	1	0.1
TIS	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
T1	255	18.2	91	13.5	84	13.3	16	11.2	15	10.6	92	13.6
T2	259	18.5	152	22.6	145	23.0	28	19.6	28	19.7	152	22.6
T3	661	47.3	376	55.9	352	55.9	83	58.0	83	58.5	376	55.8
T4	86	6.2	41	6.1	38	6.0	12	8.4	12	8.5	41	6.1
Carcinoid, Cannot be Assessed	37	2.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Not Available	88	6.3	11	1.6	9	1.4	3	2.1	3	2.1	11	1.6
Colorectal Cancer Pathologic N - Nodal Involvement												
No Form	5	0.4	1	0.1	1	0.2	0	0.0	0	0.0	1	0.1
NX	54	3.9	14	2.1	13	2.1	4	2.8	4	2.8	14	2.1
N0	786	56.2	392	58.2	372	59.0	81	56.6	81	57.0	392	58.2
N1	274	19.6	168	25.0	150	23.8	35	24.5	34	23.9	169	25.1
N2	167	11.9	88	13.1	85	13.5	20	14.0	20	14.1	88	13.1
Carcinoid, Cannot be Assessed	37	2.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Not Available	75	5.4	10	1.5	9	1.4	3	2.1	3	2.1	10	1.5

Table 2.5.3: Colorectal Tissue Availability by Colorectal Cancer Characteristics

	Colorectal											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
Pathologic M - Distant Metastasis												
No Form	5	0.4	1	0.1	1	0.2	0	0.0	0	0.0	1	0.1
MX	129	9.2	57	8.5	54	8.6	20	14.0	20	14.1	57	8.5
M0	1012	72.4	545	81.0	509	80.8	110	76.9	109	76.8	546	81.0
M1	144	10.3	61	9.1	58	9.2	10	7.0	10	7.0	61	9.1
Carcinoid, Cannot be Assessed	37	2.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Not Available	71	5.1	9	1.3	8	1.3	3	2.1	3	2.1	9	1.3
Colorectal Tumor Side/Location												
Not Applicable	18	1.3	2	0.3	2	0.3	0	0.0	0	0.0	2	0.3
Distal	651	46.6	278	41.3	261	41.4	44	30.8	43	30.3	279	41.4
Proximal	728	52.1	393	58.4	367	58.3	99	69.2	99	69.7	393	58.3
Unclear	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

Table 2.5.4: Ovary Tissue Availability by Ovarian Cancer Characteristics

	Ovarian											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
All	321	100.0	212	100.0	195	100.0	211	100.0	211	100.0	212	100.0
Ovarian Cancer Status: Ovarian Cancer Type												
Confirmed Cancer: Invasive ovarian	244	76.0	165	77.8	160	82.1	164	77.7	164	77.7	165	77.8
Confirmed Cancer: Primary peritoneal	40	12.5	25	11.8	25	12.8	25	11.8	25	11.8	25	11.8
Confirmed Cancer: Fallopian tube	13	4.0	8	3.8	8	4.1	8	3.8	8	3.8	8	3.8
Death Certificate Reported Unconfirmable: Invasive ovarian	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
Borderline Malignancy: Ovarian low malignancy potential tumor	21	6.5	12	5.7	0	0.0	12	5.7	12	5.7	12	5.7
Borderline Malignancy: Peritoneal low malignancy potential tumor	1	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Borderline Malignancy: Fallopian tube low malignancy potential tumor	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
Ovarian Cancer Type												
No form	3	0.9	3	1.4	3	1.5	3	1.4	3	1.4	3	1.4
Serous Cystadenoma	19	5.9	11	5.2	0	0.0	11	5.2	11	5.2	11	5.2
Serous Cystadenocarcinoma	179	55.8	124	58.5	124	63.6	124	58.8	124	58.8	124	58.5
Mucinous Cystadenoma	3	0.9	1	0.5	0	0.0	1	0.5	1	0.5	1	0.5
Mucinous Cystadenocarcinoma	6	1.9	5	2.4	4	2.1	5	2.4	5	2.4	5	2.4
Endometrioid Tumor	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
Endometrioid Adenocarcinoma	24	7.5	17	8.0	17	8.7	16	7.6	16	7.6	17	8.0
Clear Cell Cystadenocarcinoma	11	3.4	8	3.8	8	4.1	8	3.8	8	3.8	8	3.8
Undifferentiated Carcinoma	3	0.9	2	0.9	2	1.0	2	0.9	2	0.9	2	0.9
Other(Specify)	1	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Adenocarcinoma, NOS/ Carcinoma, NOS/ep	64	19.9	39	18.4	36	18.5	39	18.5	39	18.5	39	18.4
Granulosa Cell Tumor, Malignant	4	1.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Carcinosarcoma/Sarcoma	3	0.9	1	0.5	0	0.0	1	0.5	1	0.5	1	0.5
Ovarian Cancer Grade												
No form	3	0.9	3	1.4	3	1.5	3	1.4	3	1.4	3	1.4
Grade Cannot Be Assessed (GX)	6	1.9	2	0.9	2	1.0	2	0.9	2	0.9	2	0.9
Borderline Malignancy (GB)	23	7.2	13	6.1	1	0.5	13	6.2	13	6.2	13	6.1
Well Differentiated (G1)	17	5.3	11	5.2	10	5.1	11	5.2	11	5.2	11	5.2
Moderately Differentiated (G2)	43	13.4	32	15.1	32	16.4	31	14.7	31	14.7	32	15.1

Table 2.5.4: Ovary Tissue Availability by Ovarian Cancer Characteristics

	Ovarian											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
Poorly Differentiated (G3-4)	193	60.1	129	60.8	127	65.1	129	61.1	129	61.1	129	60.8
Unknown	36	11.2	22	10.4	20	10.3	22	10.4	22	10.4	22	10.4
Derived Ovarian Cancer Staging												
No Form	3	0.9	3	1.4	3	1.5	3	1.4	3	1.4	3	1.4
Stage I	3	0.9	2	0.9	1	0.5	2	0.9	2	0.9	2	0.9
Stage IA	35	10.9	20	9.4	14	7.2	19	9.0	19	9.0	20	9.4
Stage IB	8	2.5	5	2.4	3	1.5	5	2.4	5	2.4	5	2.4
Stage IC	22	6.9	18	8.5	16	8.2	18	8.5	18	8.5	18	8.5
Stage II	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
Stage IIA	3	0.9	2	0.9	2	1.0	2	0.9	2	0.9	2	0.9
Stage IIB	10	3.1	7	3.3	6	3.1	7	3.3	7	3.3	7	3.3
Stage IIC	14	4.4	6	2.8	5	2.6	6	2.8	6	2.8	6	2.8
Stage III	7	2.2	6	2.8	6	3.1	6	2.8	6	2.8	6	2.8
Stage IIIA	8	2.5	5	2.4	4	2.1	5	2.4	5	2.4	5	2.4
Stage IIIB	18	5.6	12	5.7	12	6.2	12	5.7	12	5.7	12	5.7
Stage IIIC	130	40.5	89	42.0	87	44.6	89	42.2	89	42.2	89	42.0
Stage IV	56	17.4	34	16.0	33	16.9	34	16.1	34	16.1	34	16.0
Can't Be Assessed	2	0.6	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
TNM not available	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
Ovarian Cancer Pathologic T (Primary Tumor)												
No form	3	0.9	3	1.4	3	1.5	3	1.4	3	1.4	3	1.4
TX	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
T0	1	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
T1	2	0.6	1	0.5	0	0.0	1	0.5	1	0.5	1	0.5
T1A	35	10.9	20	9.4	15	7.7	19	9.0	19	9.0	20	9.4
T1B	8	2.5	5	2.4	3	1.5	5	2.4	5	2.4	5	2.4
T1C	25	7.8	20	9.4	18	9.2	20	9.5	20	9.5	20	9.4
T2	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
T2A	3	0.9	2	0.9	2	1.0	2	0.9	2	0.9	2	0.9

Table 2.5.4: Ovary Tissue Availability by Ovarian Cancer Characteristics

	Ovarian											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
T2B	14	4.4	9	4.2	8	4.1	9	4.3	9	4.3	9	4.2
T2C	18	5.6	10	4.7	9	4.6	10	4.7	10	4.7	10	4.7
T3	7	2.2	6	2.8	6	3.1	6	2.8	6	2.8	6	2.8
T3A	8	2.5	5	2.4	4	2.1	5	2.4	5	2.4	5	2.4
T3B	29	9.0	22	10.4	22	11.3	22	10.4	22	10.4	22	10.4
T3C	158	49.2	104	49.1	101	51.8	104	49.3	104	49.3	104	49.1
TNM not available	8	2.5	3	1.4	2	1.0	3	1.4	3	1.4	3	1.4
Ovarian Cancer Pathologic N (Nodal Involvement)												
No form	3	0.9	3	1.4	3	1.5	3	1.4	3	1.4	3	1.4
NX	118	36.8	80	37.7	73	37.4	79	37.4	79	37.4	80	37.7
N0	142	44.2	90	42.5	81	41.5	90	42.7	90	42.7	90	42.5
N1	46	14.3	32	15.1	32	16.4	32	15.2	32	15.2	32	15.1
TNM not available	12	3.7	7	3.3	6	3.1	7	3.3	7	3.3	7	3.3
Ovarian Cancer Pathologic M (Distant Metastases)												
No form	3	0.9	3	1.4	3	1.5	3	1.4	3	1.4	3	1.4
MX	41	12.8	26	12.3	23	11.8	26	12.3	26	12.3	26	12.3
M0	217	67.6	148	69.8	136	69.7	147	69.7	147	69.7	148	69.8
M1	51	15.9	31	14.6	30	15.4	31	14.7	31	14.7	31	14.6
TNM not available	9	2.8	4	1.9	3	1.5	4	1.9	4	1.9	4	1.9

Table 2.5.5: Adenoma Tissue Availability by Adenoma Characteristics at Time of Selection

	Adenoma											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
All	2468	100.0	658	100.0	658	100.0	6	100.0	6	100.0	658	100.0
overall_stat												
Control Arm Colorectal Cancer With Adenoma	96	3.9	36	5.5	36	5.5	0	0.0	0	0.0	36	5.5
Intervention Arm Colorectal Cancer With Adenoma	131	5.3	39	5.9	39	5.9	0	0.0	0	0.0	39	5.9
ACF	217	8.8	80	12.2	80	12.2	0	0.0	0	0.0	80	12.2
Black	194	7.9	70	10.6	70	10.6	0	0.0	0	0.0	70	10.6
Recurrent	576	23.3	145	22.0	145	22.0	2	33.3	2	33.3	145	22.0
Incident	522	21.2	132	20.1	132	20.1	2	33.3	2	33.3	132	20.1
Prevalent	731	29.6	155	23.6	155	23.6	2	33.3	2	33.3	155	23.6
Other	1	0.0	1	0.2	1	0.2	0	0.0	0	0.0	1	0.2
Adenoma Recurrency Status												
Double Recurrent	418	16.9	125	19.0	125	19.0	1	16.7	1	16.7	125	19.0
Second Recurrent	52	2.1	11	1.7	11	1.7	0	0.0	0	0.0	11	1.7
First Recurrent	184	7.5	45	6.8	45	6.8	1	16.7	1	16.7	45	6.8
Other Case	1814	73.5	477	72.5	477	72.5	4	66.7	4	66.7	477	72.5
Adenoma Size												
Small	801	32.5	166	25.2	166	25.2	1	16.7	1	16.7	166	25.2
Large	1667	67.5	492	74.8	492	74.8	5	83.3	5	83.3	492	74.8
Year of first Adenoma												
T0	1697	68.8	455	69.1	455	69.1	4	66.7	4	66.7	455	69.1
T35	566	22.9	152	23.1	152	23.1	2	33.3	2	33.3	152	23.1
1st SCU, at or After T35	55	2.2	7	1.1	7	1.1	0	0.0	0	0.0	7	1.1
2nd SCU	14	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Adenoma in Cancer Year	136	5.5	44	6.7	44	6.7	0	0.0	0	0.0	44	6.7
Source of Recurrence Information												
Missing	1814	73.5	477	72.5	477	72.5	4	66.7	4	66.7	477	72.5
T0	591	23.9	170	25.8	170	25.8	2	33.3	2	33.3	170	25.8

Table 2.5.5: Adenoma Tissue Availability by Adenoma Characteristics at Time of Selection

	Adenoma											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
T35	7	0.3	2	0.3	2	0.3	0	0.0	0	0.0	2	0.3
SCU	56	2.3	9	1.4	9	1.4	0	0.0	0	0.0	9	1.4

Table 2.5.6: Female-Breast Tissue Availability by Breast Cancer Characteristics

	Breast											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
All	1852	100.0	801	100.0	801	100.0	768	100.0	768	100.0	801	100.0
Breast Cancer Status												
Confirmed Cancer	1242	67.1	692	86.4	692	86.4	669	87.1	669	87.1	692	86.4
Confirmed In Situ	610	32.9	109	13.6	109	13.6	99	12.9	99	12.9	109	13.6
Breast Cancer Type												
Lobular	200	10.8	100	12.5	100	12.5	95	12.4	95	12.4	100	12.5
Tubular	49	2.6	15	1.9	15	1.9	13	1.7	13	1.7	15	1.9
Ductal, NOS	1343	72.5	599	74.8	599	74.8	575	74.9	575	74.9	599	74.8
Other	260	14.0	87	10.9	87	10.9	85	11.1	85	11.1	87	10.9
Breast Cancer Grade												
Well differentiated; Grade I	344	18.6	164	20.5	164	20.5	153	19.9	153	19.9	164	20.5
Moderately differentiated; Grade II	582	31.4	297	37.1	297	37.1	288	37.5	288	37.5	297	37.1
Poorly differentiated; Grade III	513	27.7	257	32.1	257	32.1	250	32.6	250	32.6	257	32.1
Undifferentiated; Grade IV	8	0.4	3	0.4	3	0.4	3	0.4	3	0.4	3	0.4
Not determined/stated/or applicable	405	21.9	80	10.0	80	10.0	74	9.6	74	9.6	80	10.0
Breast Cancer Stage												
No BCS Form	43	2.3	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
0	572	30.9	109	13.6	109	13.6	99	12.9	99	12.9	109	13.6
I	722	39.0	377	47.1	377	47.1	357	46.5	357	46.5	377	47.1
IIA	307	16.6	189	23.6	189	23.6	186	24.2	186	24.2	189	23.6
IIB	138	7.5	83	10.4	83	10.4	83	10.8	83	10.8	83	10.4
IIIA	31	1.7	20	2.5	20	2.5	20	2.6	20	2.6	20	2.5
IIIB	27	1.5	15	1.9	15	1.9	15	2.0	15	2.0	15	1.9
IV	9	0.5	7	0.9	7	0.9	7	0.9	7	0.9	7	0.9
Missing Components	3	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Breast Cancer Behavior												
In situ	611	33.0	109	13.6	109	13.6	99	12.9	99	12.9	109	13.6
Malignant, primary site	558	30.1	294	36.7	294	36.7	282	36.7	282	36.7	294	36.7
Malignant, invasive with in situ components	683	36.9	398	49.7	398	49.7	387	50.4	387	50.4	398	49.7

Table 2.5.6: Female-Breast Tissue Availability by Breast Cancer Characteristics

	Breast											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
Breast Cancer Tumor Size												
No BCS Form	43	2.3	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
Missing	582	31.4	111	13.9	111	13.9	101	13.2	101	13.2	111	13.9
0 cm to less than 2 cm	883	47.7	478	59.7	478	59.7	457	59.5	457	59.5	478	59.7
2 cm to less than 5 cm	315	17.0	190	23.7	190	23.7	188	24.5	188	24.5	190	23.7
5 cm or more	29	1.6	21	2.6	21	2.6	21	2.7	21	2.7	21	2.6
Breast Cancer Topography												
Nipple	22	1.2	5	0.6	5	0.6	4	0.5	4	0.5	5	0.6
Central portion of breast	137	7.4	48	6.0	48	6.0	45	5.9	45	5.9	48	6.0
Upper inner quadrant of breast	173	9.3	80	10.0	80	10.0	75	9.8	75	9.8	80	10.0
Lower inner quadrant of breast	112	6.0	52	6.5	52	6.5	51	6.6	51	6.6	52	6.5
Upper outer quadrant of breast	672	36.3	300	37.5	300	37.5	291	37.9	291	37.9	300	37.5
Lower outer quadrant of breast	131	7.1	71	8.9	71	8.9	70	9.1	70	9.1	71	8.9
Axillary tail of breast	5	0.3	2	0.2	2	0.2	2	0.3	2	0.3	2	0.2
Overlapping lesion of breast	420	22.7	181	22.6	181	22.6	171	22.3	171	22.3	181	22.6
Breast NOS	180	9.7	62	7.7	62	7.7	59	7.7	59	7.7	62	7.7
ER - Status												
No BCS Form	43	2.3	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
Negative	364	19.7	203	25.3	203	25.3	200	26.0	200	26.0	203	25.3
Equivocal - positive cells within range of 1-9%	22	1.2	16	2.0	16	2.0	16	2.1	16	2.1	16	2.0
Positive	1046	56.5	492	61.4	492	61.4	469	61.1	469	61.1	492	61.4
Not Available	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
Ordered, No results	8	0.4	2	0.2	2	0.2	2	0.3	2	0.3	2	0.2
Not Ordered	368	19.9	86	10.7	86	10.7	79	10.3	79	10.3	86	10.7
PR - Status												
No BCS Form	43	2.3	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
Negative	615	33.2	329	41.1	329	41.1	317	41.3	317	41.3	329	41.1
Equivocal - positive cells within range of 1-9%	106	5.7	64	8.0	64	8.0	63	8.2	63	8.2	64	8.0
Positive	701	37.9	314	39.2	314	39.2	301	39.2	301	39.2	314	39.2

Table 2.5.6: Female-Breast Tissue Availability by Breast Cancer Characteristics

	Breast											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
Indeterminant	4	0.2	2	0.2	2	0.2	2	0.3	2	0.3	2	0.2
Not Available	2	0.1	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
Ordered, No results	8	0.4	2	0.2	2	0.2	2	0.3	2	0.3	2	0.2
Not Ordered	373	20.1	88	11.0	88	11.0	81	10.5	81	10.5	88	11.0
HER2 Status												
No BCS Form	43	2.3	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
Positive	145	7.8	73	9.1	73	9.1	71	9.2	71	9.2	73	9.1
Equivocal	65	3.5	44	5.5	44	5.5	44	5.7	44	5.7	44	5.5
Negative	693	37.4	386	48.2	386	48.2	368	47.9	368	47.9	386	48.2
Indeterminant	17	0.9	12	1.5	12	1.5	11	1.4	11	1.4	12	1.5
Ordered, No results	889	48.0	285	35.6	285	35.6	273	35.5	273	35.5	285	35.6

Table 2.5.7: Male-Breast Tissue Availability by Breast Cancer Characteristics

	Male Breast											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
All	27	100.0	17	100.0	17	100.0	17	100.0	17	100.0	17	100.0
Breast Cancer Status												
Confirmed Cancer	25	92.6	16	94.1	16	94.1	16	94.1	16	94.1	16	94.1
Confirmed In Situ	2	7.4	1	5.9	1	5.9	1	5.9	1	5.9	1	5.9
Breast Cancer Behavior												
In situ	2	7.4	1	5.9	1	5.9	1	5.9	1	5.9	1	5.9
Malignant, primary site	25	92.6	16	94.1	16	94.1	16	94.1	16	94.1	16	94.1
Breast Cancer Grade												
Well differentiated; Grade I	6	22.2	5	29.4	5	29.4	5	29.4	5	29.4	5	29.4
Moderately differentiated; Grade II	12	44.4	6	35.3	6	35.3	6	35.3	6	35.3	6	35.3
Poorly differentiated; Grade III	4	14.8	4	23.5	4	23.5	4	23.5	4	23.5	4	23.5
Not determined/stated/or applicable	5	18.5	2	11.8	2	11.8	2	11.8	2	11.8	2	11.8
Breast Cancer Morphology												
8010 - Carcinoma NOS	1	3.7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
8050 - Papillary carcinoma NOS	1	3.7	1	5.9	1	5.9	1	5.9	1	5.9	1	5.9
8201 - Cribriform carcinoma	1	3.7	1	5.9	1	5.9	1	5.9	1	5.9	1	5.9
8500 - Infiltrating duct carcinoma	23	85.2	15	88.2	15	88.2	15	88.2	15	88.2	15	88.2
8504 - Intracystic carcinoma NOS	1	3.7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

Table 2.5.8: Bladder Tissue Availability by Bladder Cancer Characteristics

	Bladder											
	Selected by IMS		*With TMA Cores*		*With TMA Tumor Cores*		*With DNA Cores*		*With TMA Cores and DNA Cores*		*With TMA Cores or DNA Cores*	
	N	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*	*N*	*%*
All	880	100.0	201	100.0	201	100.0	124	100.0	124	100.0	201	100.0
Bladder Cancer Status												
Confirmed Cancer	624	70.9	156	77.6	156	77.6	102	82.3	102	82.3	156	77.6
Confirmed In Situ	252	28.6	45	22.4	45	22.4	22	17.7	22	17.7	45	22.4
Borderline Malignancy	4	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Bladder Cancer Behavior												
Uncertain, borderline, or LMP	4	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
In situ	252	28.6	45	22.4	45	22.4	22	17.7	22	17.7	45	22.4
Malignant, primary site	624	70.9	156	77.6	156	77.6	102	82.3	102	82.3	156	77.6
Bladder Cancer Grade												
Well differentiated; Grade I	210	23.9	46	22.9	46	22.9	27	21.8	27	21.8	46	22.9
Moderately differentiated; Grade II	186	21.1	44	21.9	44	21.9	29	23.4	29	23.4	44	21.9
Poorly differentiated; Grade III	288	32.7	79	39.3	79	39.3	53	42.7	53	42.7	79	39.3
Undifferentiated; Grade IV	46	5.2	13	6.5	13	6.5	5	4.0	5	4.0	13	6.5
Not determined/stated/or applicable	150	17.0	19	9.5	19	9.5	10	8.1	10	8.1	19	9.5
Bladder Cancer Morphology												
8010 - Carcinoma NOS	7	0.8	1	0.5	1	0.5	1	0.8	1	0.8	1	0.5
8020	2	0.2	1	0.5	1	0.5	0	0.0	0	0.0	1	0.5
8050 - Papillary carcinoma NOS	9	1.0	1	0.5	1	0.5	0	0.0	0	0.0	1	0.5
8120	323	36.7	67	33.3	67	33.3	49	39.5	49	39.5	67	33.3
8130	537	61.0	130	64.7	130	64.7	73	58.9	73	58.9	130	64.7
8980	2	0.2	1	0.5	1	0.5	1	0.8	1	0.8	1	0.5